Which companies disclosed the most to Open Payments

Genentech, the maker of Avastin and other expensive cancer drugs, paid physicians and teaching hospitals more than any other drug or device company in 2014, according to a new round of data published Tuesday on the CMS’ Open Payments website.

The data reveal payments made for research, gifts, speaking fees, meals and travel.

South San Francisco-based Genentech, now a subsidiary of Roche, disclosed $295.4 million in general payments made in 2014, almost four times as much as AstraZeneca, the company with the next highest tally. The majority of that sum—$254.9 million—reflects royalty payments made to City of Hope, the California comprehensive cancer center that holds the patents on research underlying Genentech’s biggest drugs, Avastin, Rituxan and Herceptin.

Genentech also noted in a statement that it paid one physician $2.8 million and another $10.1 million to fulfill agreements they had with Seragon, a company Genentech acquired last year.

The median amount from all companies paid to physicians in 2014 was $233,376, and 125 companies paid more than $1 million. All told, the top 10 companies paid $709 million.